CA2613466A1 - Nanoparticulate megestrol formulations - Google Patents

Nanoparticulate megestrol formulations Download PDF

Info

Publication number
CA2613466A1
CA2613466A1 CA002613466A CA2613466A CA2613466A1 CA 2613466 A1 CA2613466 A1 CA 2613466A1 CA 002613466 A CA002613466 A CA 002613466A CA 2613466 A CA2613466 A CA 2613466A CA 2613466 A1 CA2613466 A1 CA 2613466A1
Authority
CA
Canada
Prior art keywords
less
megestrol
composition
nanoparticulate
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002613466A
Other languages
English (en)
French (fr)
Inventor
Douglas Hovey
John Pruitt
Tuula Ryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International, Limited
Douglas Hovey
John Pruitt
Tuula Ryde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International, Limited, Douglas Hovey, John Pruitt, Tuula Ryde filed Critical Elan Pharma International, Limited
Publication of CA2613466A1 publication Critical patent/CA2613466A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002613466A 2005-06-22 2006-06-22 Nanoparticulate megestrol formulations Abandoned CA2613466A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69312705P 2005-06-22 2005-06-22
US60/693,127 2005-06-22
PCT/US2006/024349 WO2007002315A2 (en) 2005-06-22 2006-06-22 Nanoparticulate megestrol formulations

Publications (1)

Publication Number Publication Date
CA2613466A1 true CA2613466A1 (en) 2007-01-04

Family

ID=37595838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002613466A Abandoned CA2613466A1 (en) 2005-06-22 2006-06-22 Nanoparticulate megestrol formulations

Country Status (13)

Country Link
EP (1) EP1901713A2 (ja)
JP (1) JP2008546796A (ja)
KR (1) KR20080024213A (ja)
CN (1) CN101242810A (ja)
AU (1) AU2006262144A1 (ja)
BR (1) BRPI0612665A2 (ja)
CA (1) CA2613466A1 (ja)
EA (1) EA200800099A1 (ja)
IL (1) IL188322A0 (ja)
MX (1) MX2008000396A (ja)
NO (1) NO20080403L (ja)
WO (1) WO2007002315A2 (ja)
ZA (1) ZA200800376B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105147605B (zh) * 2015-06-24 2019-04-19 中国人民解放军军事医学科学院毒物药物研究所 黄体酮纳米组合物及其制备方法
CN105687027A (zh) * 2016-01-26 2016-06-22 中国科学院生物物理研究所 一种无醇氨基酸型免冲洗泡沫洗液
CN105769763A (zh) * 2016-05-25 2016-07-20 西安德天药业股份有限公司 一种醋酸甲地孕酮纳米混悬液及其制备方法和应用
CN108409821A (zh) * 2018-03-19 2018-08-17 青岛国海生物制药有限公司 一种醋酸甲地孕酮纳米结晶的制备方法及醋酸甲地孕酮
CN108309933A (zh) * 2018-03-19 2018-07-24 青岛国海生物制药有限公司 一种口服醋酸甲地孕酮纳米混悬液及其制备方法
CN112891309B (zh) * 2019-11-19 2022-07-26 北京化工大学 一种醋酸甲地孕酮纳米干混悬剂及其制备方法
CN111643463A (zh) * 2020-07-08 2020-09-11 西安远大德天药业股份有限公司 一种醋酸甲地孕酮分散片及其制备方法
CN111930838B (zh) * 2020-07-23 2023-05-16 金陵科技学院 一种面向时间的分布式档案管理方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO2003086354A1 (en) * 2002-04-12 2003-10-23 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
JP4787165B2 (ja) * 2003-11-05 2011-10-05 エラン ファーマ インターナショナル，リミティド 表面安定剤としてペプチドを有するナノ粒子組成物

Also Published As

Publication number Publication date
KR20080024213A (ko) 2008-03-17
NO20080403L (no) 2008-03-19
WO2007002315A3 (en) 2007-04-05
CN101242810A (zh) 2008-08-13
ZA200800376B (en) 2009-03-25
EP1901713A2 (en) 2008-03-26
JP2008546796A (ja) 2008-12-25
BRPI0612665A2 (pt) 2010-11-30
WO2007002315A2 (en) 2007-01-04
IL188322A0 (en) 2008-04-13
AU2006262144A1 (en) 2007-01-04
EA200800099A1 (ru) 2008-06-30
MX2008000396A (es) 2009-02-23

Similar Documents

Publication Publication Date Title
US9101549B2 (en) Nanoparticulate megestrol formulations
US7101576B2 (en) Nanoparticulate megestrol formulations
EP1658053B1 (en) Novel compositions of sildenafil free base
US20040105889A1 (en) Low viscosity liquid dosage forms
AU2006309295B2 (en) Nanoparticulate acetaminophen formulations
US20040018242A1 (en) Nanoparticulate nystatin formulations
CA2613466A1 (en) Nanoparticulate megestrol formulations
JP2010248220A (ja) ナノ粒子メゲストロール製剤
CA2631757A1 (en) Novel mometasone compositions and methods of making and using the same
US20120087955A1 (en) Nanoparticulate megestrol formulations
EP1935407A1 (en) Low viscosity liquid dosage forms

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140422